Refractive outcome shifts toward myopia after combined surgery

Article

Postoperative refractive outcome shifts toward myopia in patients being treated for rhegmatogenous retinal detachment (RRD) with the combination of phacoemulsification and pars plana vitrectomy, compared with patients who underwent combined surgery for other vitreoretinal pathologies

Postoperative refractive outcome shifts toward myopia in patients being treated for rhegmatogenous retinal detachment (RRD) with the combination of phacoemulsification and pars plana vitrectomy, compared with patients who underwent combined surgery for other vitreoretinal pathologies, according to an article published online in the American Journal of Ophthalmology.

Researchers in South Korea conducted a retrospective observational case-control study of 55 patients. All of the patients had had a combined surgery between January 2007 and December 2012: 25 for RRD (the RRD group), and 30 for other vitreoretinal pathology (the control group). They found that the RRD group had a mean shift toward myopia of 0.35 D compared with the control group.

The mean difference between the predicted refractive outcome and the actual postoperative outcome was –0.43 D ± 0.67 (P = 0.046) in the RRD group and –0.08 D ± 0.53 (P = 0.767) in the control group. The mean preoperative intraocular pressure (IOP) was 11.44 mmHg ± 3.15 in the affected eye in the RRD group, and 13.16 mmHg ± 2.73 in the fellow eye (P = 0.045); there was no IOP difference in the affected eye (14.20 mmHg ± 2.95) and fellow eye (14.17 mmHg ± 3.50) in the control group (P = 0.974).

Postoperatively, there was no significant IOP difference in the affected and fellow eyes of both groups. In the RRD group, the refractive difference for all eyes correlated to IOP change (r = 0.659, r2 = 0.435, P

To read an abstract of the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.